gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Taysha Gene Therapies

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABO-202

            Therapeutic Area: Genetic Disease Product Name: ABO-202

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Recipient: Abeona Therapeutics

            Deal Size: $63.0 million Upfront Cash: $7.0 million

            Deal Type: Licensing Agreement September 11, 2020

            Details:

            The agreements grant Taysha worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill (UNC) and Abeona, and Abeona know-how relating to the research, development, and manufacture of ABO-202.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TSHA-101

            Therapeutic Area: Genetic Disease Product Name: TSHA-101

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            Taysha Gene Therapies has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for TSHA-101, an AAV9-based gene therapy in development for GM2 Gangliosidosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABO-202

            Therapeutic Area: Genetic Disease Product Name: ABO-202

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Recipient: Abeona Therapeutics

            Deal Size: $63.0 million Upfront Cash: $3.0 million

            Deal Type: Licensing Agreement August 17, 2020

            Details:

            The agreements grant Taysha worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill (UNC) and Abeona, and Abeona know-how relating to the research, development, and manufacture of ABO-202.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TSHA-101

            Therapeutic Area: Genetic Disease Product Name: TSHA-101

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Fidelity Management & Research Company

            Deal Size: $95.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing August 05, 2020

            Details:

            Financing will go in advancing initial cohort of lead programs into the clinic, accelerate progress on anticipated IND submissions, build a commercially scalable GMP manufacturing facility and continue development of the company’s extensive portfolio.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TGTX-101

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: PBM Capital

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Financing April 29, 2020

            Details:

            Financing would assist in meeting Taysha's goal of advancing its 15 AAV gene therapy programs pipeline with options for another four programs targeting central nervous system diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV gene therapies

            Therapeutic Area: Neurology Product Name: TGTX-101

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Recipient: UT Southwestern

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 29, 2020

            Details:

            UT Southwestern will conduct preclinical research, lead IND-enabling studies, provide clinical GMP manufacturing, as well as execute natural history studies on Taysha's AAV gene therapies.